Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

781
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
781
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.9K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

55
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
55
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

97
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
97

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

Impact of Revascularization Completeness on Cardiovascular Outcomes in STEMI With Multivessel Disease.

Circulation. Cardiovascular interventions·2026
Same author

Stent thrombosis associated with non-response to clopidogrel despite co-administration of aspirin and ibrutinib.

European heart journal. Case reports·2026
Same author

Invasive vs Conservative Strategy for Frail Older Patients With Myocardial Infarction: A Secondary Analysis of the SENIOR-RITA Randomized Clinical Trial.

JAMA network open·2026
Same author

Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts.

International journal of chronic obstructive pulmonary disease·2026
Same author

Comparing anti-platelet and anti-thrombin therapies in the ischaemia-reperfusion injured coronary microcirculation of healthy and diabetic mice.

Basic research in cardiology·2026
Same journal

The Influence of Congenital Heart Defect Repair Through a Right Subaxillary Thoracotomy on Postoperative Pulmonary Function and Prognosis in Small Infants.

Reviews in cardiovascular medicine·2026
Same journal

Left Ventricular Hypertrabeculation: Historical Evolution, Diagnostic Pitfalls, and a Pragmatic Clinical Approach.

Reviews in cardiovascular medicine·2026
Same journal

Study on the Role and Mechanism of γδ T Cells in Atherosclerosis Under a High-Fat Diet.

Reviews in cardiovascular medicine·2026
Same journal

The Role of Stress Granules in Cardiovascular Diseases.

Reviews in cardiovascular medicine·2026
Same journal

Computed Tomography-Based Radiomics Provides New Insights Into Associations Between Pericoronary Fat Characteristics and Low-Density Lipoprotein Cholesterol.

Reviews in cardiovascular medicine·2026
Same journal

Association of Triglyceride-Glucose Index With In-Hospital Malignant Arrhythmias in Older Patients With Diabetes Mellitus and Left Ventricular Aneurysm: A Retrospective Study.

Reviews in cardiovascular medicine·2026
See all related articles

Related Experiment Video

Updated: Oct 29, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.2K

Ticagrelor: clinical development and future potential.

Nicholas C Sanderson1, William A E Parker1,2, Robert F Storey1,2

  • 1Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, S10 2RX Sheffield, UK.

Reviews in Cardiovascular Medicine
|July 14, 2021
PubMed
Summary
This summary is machine-generated.

Ticagrelor, a P2Y12 receptor antagonist, offers potent antiplatelet effects for managing atherothrombosis. Future strategies may involve ticagrelor monotherapy or combination therapy with low-dose aspirin to balance efficacy and bleeding risk.

Keywords:
Acute coronary syndromeAspirinChronic coronary syndromesCoronary artery bypass graftingCoronary artery diseaseDual antiplatelet therapyP2Y12 receptorPercutaneous coronary interventionTicagrelor

More Related Videos

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

18.0K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.5K

Related Experiment Videos

Last Updated: Oct 29, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.2K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

18.0K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.5K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Thrombosis Research

Background:

  • Platelets are central to atherothrombosis, leading to vessel occlusion and ischemia.
  • Optimizing antiplatelet therapy can reduce morbidity and mortality from atherosclerosis.

Purpose of the Study:

  • To review the characteristics and clinical applications of ticagrelor.
  • To explore novel strategies for antiplatelet therapy to minimize bleeding risk.

Main Methods:

  • Review of pharmacological properties of ticagrelor, including P2Y12 receptor antagonism, onset/offset kinetics, and pleiotropic effects.
  • Analysis of clinical outcomes data from studies involving ticagrelor in various cardiovascular conditions.
  • Discussion of emerging treatment paradigms, such as ticagrelor monotherapy and modified dual antiplatelet therapy.

Main Results:

  • Ticagrelor demonstrates potent, consistent P2Y12 inhibition with rapid onset/offset and is amenable to reversal.
  • Clinical benefits observed in acute coronary syndromes, ischemic stroke, and post-percutaneous coronary intervention.
  • Efficacy not definitively established post-coronary artery bypass graft or in peripheral artery disease.

Conclusions:

  • Ticagrelor's unique properties offer advantages in managing atherothrombosis.
  • Future management may involve personalized antithrombotic strategies, including ticagrelor monotherapy or tailored dual therapy.
  • Balancing ischemic risk and bleeding risk is crucial for optimizing patient outcomes.